How does AstraZeneca's trial pause affect other COVID-19 vaccines? Analysts weigh in AstraZeneca's COVID-19 vaccine hold sparks reassessment of race NIH Director Collins says future COVID-19 vaccine approvals will follow science or 'I will have no part of it' Pfizer, BioNTech near Euro supply deal for up to 300M doses of COVID-19 vaccine Why Walmart Health's chief just left the 'dream job' to lead a testing company you've never heard of Qiagen, Ellume to build portable antigen-testing hubs for COVID-19 Catalent injects $130M into Maryland cell and gene therapy site drafted into COVID-19 vaccine hunt OncoImmune nabs $56M round for late-stage COVID-19 tests, leukemia treatment Healthcare roundup: Independence Blue Cross to offer nearly $120M on premium rebates, credits Biopharma roundup: AstraZeneca's clinical hold could boost rival, stall trials, analysts think Pfizer, BioNTech report ‘strong’ immune response in animals to COVID-19 mRNA vaccine candidate AstraZeneca's COVID-19 vaccine production partner Emergent not likely to suffer if trial hold sticks: analysts Featured Story | By Eric Sagonowsky In the wake of stunning news yesterday that AstraZeneca paused its phase 3 COVID-19 vaccine trial due to a serious safety issue, analysts across the biopharma landscape set out to answer questions, and lay out possible scenarios, about how the race could play out from here. read more |
| |
|---|
|
Top Stories By Nick Paul Taylor AstraZeneca has put clinical development of its COVID-19 vaccine on hold in response to an adverse event, sparking a reassessment of the race to bring a coronavirus prophylactic to market. read more By Tina Reed Surgeon general on COVID-19 vaccine development: "There will be no shortcuts." read more By Kyle Blankenship In the hunt for a COVID-19 vaccine, no front-runner is moving as quickly as Pfizer and BioNTech's mRNA-based shot, which is scoping an October regulatory review. Despite some technical concerns about their proposed rollout plans, the partners are moving ahead with their largest supply deal yet. read more By Tina Reed As president of Walmart Health, Sean Slovenski was sitting in one of the most influential positions when it came to U.S. healthcare. So, why did he just leave the gig to work at a far smaller firm that specializes in diagnostic testing? The answer is complicated, Slovenski said. read more By Conor Hale Shortly after unveiling a portable, digital testing system for COVID-19 antibodies late last month, Qiagen has now announced plans to leverage the same platform for a rapid antigen test to identify active coronavirus infections. read more By Kyle Blankenship New Jersey contract manufacturer Catalent has been right in the mix in the COVID-19 response effort, signing pacts to help produce frontrunners in the vaccine hunt. Now, the company is fleshing out a Maryland facility to aid in that effort—and position Catalent's cell and gene therapy offerings well into the future. read more By Ben Adams OncoImmune has raised $56 million in a series B as it looks to push on with late-stage tests for its experimental drug CD24Fc in both leukemia patients and its recent pivot to COVID-19. read more By Healthcare Staff Follow along with the latest COVID-19 news straight from the Fierce Healthcare team. read more By Eric Sagonowsky, Angus Liu, Kyle Blankenship, Conor Hale, Fraiser Kansteiner AstraZeneca's clinical hold may slow the pace of other vaccine trials, analysts figure. Pfizer and BioNTech's shot hopeful yielded strong immune data in animals. Sinovac's vaccine spurred a safe immune response in older adults. Catalent is expanding the Maryland site where it will produce AZ shots. And Qiagen plans to launch a rapid antigen test. read more By Arlene Weintraub Pfizer and its partner BioNTech said Wednesday that their most advanced COVID-19 vaccine candidate produced neutralizing antibodies against the virus in macaques, as well as T cell responses that are believed to be an indicator of a strong immune attack. The data formed the basis of the current phase 2/3 trial in people. read more By Kyle Blankenship AstraZeneca was humming right along with its partnered COVID-19 vaccine with the University of Oxford before a sudden trial hold threw its plans into disarray. So what does that uncertainty mean for AstraZeneca's expectant manufacturing partners on the shot? For at least one, it could be no issue at all. read more |
